⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8705311 | 1.00 | — | — | |
| SCHEMBL186805 | 1.00 | — | — | |
| Ether SCHEMBL10944562 | 0.87 | — | — | |
| SCHEMBL11637903 | 0.82 | — | — | |
| SCHEMBL11640189 | 0.79 | — | — | |
| SCHEMBL11633458 | 0.77 | — | — | |
| SCHEMBL12850800 | 0.76 | — | — | |
| SCHEMBL19128726 | 0.76 | — | — | |
| SCHEMBL765223 | 0.76 | — | — | |
| SCHEMBL3637989 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028356-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250066388-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORS | ABBVIE INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-119053610-A | 1,3,4, 7-Tetrahydro-2H-pyrrolo [3',2':5,6] pyrido [2,3-b ] [1,4] oxazepine Bcl-2 inhibitors | 艾伯维公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12129274-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-11964990-B2 | 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors | ABBVIE INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023141536-A1 | 1,3,4,7-TETRAHYDRO-2H-PYRROLO [3',2':5,6] PYRIDO[2,3-B] [1,4] OXAZEPINE BC1-2 INHIBITORS | ABBVIE INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230234971-A1 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors | ABBVIE INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673907-B2 | Modular synthesis of aminoglycosides | REVAGENIX, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2019194858-A1 | MODULAR SYNTHESIS OF AMINOGLYCOSIDES | ACHAOGEN, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019046126-A1 | AMINOGLYCOSIDES AND USES THEREOF | ACHAOGEN, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046126-A1 | AMINOGLYCOSIDES AND USES THEREOF | ACHAOGEN, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1802316-B1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863253-B2 | Purine Derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-01-04 | — | — | US | disclosed |